CNTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Context Therapeutics Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$0.24−0.01 (-2.30%)
Close on Oct 19, 2026
- Market cap
- $22.69M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
68.4%
63M of 92M shares
Institutional holders
79
36 new, 15 sold out
Net institutional buying
-16M
In Q2 2026
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Michael Gregory | 9,200,580 | 9.90% | 13G (passive) amendment | Sep 30, 2025 |
| Avidity Capital Partners (GP) LLC | 8,302,808 | 8.70% | 13G (passive) amendment | Mar 31, 2026 |
| Avidity Private Master Fund I LP | 7,776,296 | 9.90% | 13G (passive) amendment | Dec 31, 2024 |
| Ian Charoub | 7,419,355 | 9.90% | 13G (passive) | May 6, 2024 |
| David Kroin | 7,419,355 | 8.27% | 13G (passive) amendment | Mar 31, 2025 |
| Soleus Capital Management, L.P. | 6,963,141 | 7.60% | 13G (passive) amendment | Mar 31, 2026 |
| BlackRock, Inc. | 6,169,250 | 6.70% | 13G (passive) | Jun 30, 2026 |
| Octagon Capital Advisors LP | 5,250,000 | 5.70% | 13G (passive) | Mar 31, 2026 |
| Soleus Capital Group, LLC | 4,776,398 | 5.20% | 13G (passive) | Feb 2, 2026 |
| Dr. Jeffrey R. Jay, M.D. | 4,683,711 | 5.10% | 13G (passive) amendment | Dec 31, 2025 |
| Ms. Lillian Nordahl | 4,683,711 | 6.25% | 13G (passive) amendment | Dec 31, 2024 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of CNTX | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Deep Track Capital, LP | 7,419,355 | 8.08% | $4.11M | – | 0.06% |
| Nextech Invest, Ltd. | 7,419,355 | 8.08% | $4.11M | – | 0.20% |
| Soleus Capital Management, L.P. | 7,063,141 | 7.69% | $3.91M | +100,000 | 0.13% |
| BlackRock, Inc. | 6,169,250 | 6.71% | $3.42M | +5,322,554 | 0.00% |
| Avidity Partners Management LP | 4,998,267 | 5.44% | $2.77M | −4,998,267 | 0.44% |
| Franklin Resources Inc | 3,803,338 | 4.14% | $2.11M | – | 0.00% |
| Vanguard Capital Management LLC | 3,432,052 | 3.74% | $1.90M | +99 | 0.00% |
| Octagon Capital Advisors LP | 3,050,000 | 3.32% | $1.69M | −2,200,000 | 0.15% |
| Blue Owl Capital Holdings LP | 2,934,015 | 3.19% | $1.63M | −2,155,000 | 0.24% |
| TCG Crossover Management, LLC | 2,682,696 | 2.92% | $1.49M | – | 0.04% |
| Geode Capital Management, LLC | 1,830,309 | 1.99% | $1.01M | +1,226,542 | 0.00% |
| State Street Corp | 1,413,428 | 1.54% | $782.90K | +1,179,921 | 0.00% |
| Mpm Bioimpact LLC | 1,299,046 | 1.41% | $719.54K | −9,380,345 | 0.04% |
| Renaissance Technologies LLC | 1,041,399 | 1.13% | $576.83K | +858,400 | 0.00% |
| Acadian Asset Management LLC | 1,010,904 | 1.10% | $559 | New | 0.00% |
| ADAR1 Capital Management, LLC | 750,969 | 0.82% | $415.96K | +399,875 | 0.02% |
| Jane Street Group, LLC | 645,209 | 0.70% | $357.38K | +208,278 | 0.00% |
| Vanguard Portfolio Management LLC | 638,878 | 0.70% | $353.94K | New | 0.00% |
| Northern Trust Corp | 615,576 | 0.67% | $340.97K | +512,320 | 0.00% |
| Vanguard Fiduciary Trust Co | 433,888 | 0.47% | $240.37K | +92,544 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 79 | 63M | 68.4% | 36 / 19 | 13 / 15 | 14M | 31M |
| Q1 2026 | 59 | 79M | 86.2% | 25 / 10 | 13 / 7 | 29M | 11M |
| Q4 2025 | 43 | 65M | 71.1% | 10 / 8 | 8 / 4 | 6M | 10M |
| Q3 2025 | 37 | 69M | 75.1% | 6 / 6 | 7 / 7 | 2M | 2M |
| Q2 2025 | 39 | 69M | 74.7% | 4 / 9 | 9 / 7 | 1M | 3M |
| Q1 2025 | 42 | 71M | 77.7% | 3 / 6 | 14 / 12 | 9M | 3M |
| Q4 2024 | 52 | 73M | 79.2% | 14 / 15 | 12 / 4 | 21M | 5M |
| Q3 2024 | 42 | 57M | 61.7% | 15 / 6 | 11 / 6 | 5M | 7M |
| Q2 2024 | 34 | 59M | 64.2% | 19 / 8 | 3 / 9 | 56M | 1M |
| Q1 2024 | 25 | 4M | 4.3% | 4 / 6 | 2 / 3 | 0M | 0M |
| Q4 2023 | 24 | 4M | 3.9% | 2 / 7 | 1 / 1 | 1M | 0M |
| Q3 2023 | 23 | 3M | 2.8% | 3 / 7 | 1 / 2 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of CNTX | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2,815,486 | 3.06% | $1.56M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 2,329,496 | 2.54% | $1.29M | 0.00% | Jun 30, 2026 |
| Franklin Biotechnology Discovery Fund | 1,398,833 | 1.52% | $838.46K | 0.07% | Jul 31, 2026 |
| Fidelity Small Cap Index Fund | 1,008,220 | 1.10% | $604.33K | 0.00% | Jul 31, 2026 |
| iShares Russell 2000 Growth ETF | 874,891 | 0.95% | $484.60K | 0.00% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 520,997 | 0.57% | $288.58K | 0.00% | Jun 30, 2026 |
| iShares Micro-Cap ETF | 313,131 | 0.34% | $173.44K | 0.01% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 250,259 | 0.27% | $713.24K | 0.00% | May 31, 2026 |
| Schwab Small-Cap Index Fund | 227,850 | 0.25% | $136.57K | 0.00% | Jul 31, 2026 |
| Master Small Cap Index Series | 203,375 | 0.22% | $112.65K | 0.00% | Jun 30, 2026 |
| Nuveen Small Cap Blend Index Fund | 125,518 | 0.14% | $75.24K | 0.00% | Jul 31, 2026 |
| EQ/2000 Managed Volatility Portfolio | 103,736 | 0.11% | $57.46K | 0.00% | Jun 30, 2026 |
| Fidelity Total Market Index Fund | 97,615 | 0.11% | $278.20K | 0.00% | May 31, 2026 |
| Fidelity Small Cap Growth Index Fund | 88,395 | 0.10% | $48.96K | 0.00% | Jun 30, 2026 |
| Fidelity Series Total Market Index Fund | 72,616 | 0.08% | $206.96K | 0.00% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Martin A. Lehr | Chief Executive Officer, Director | 1,079,891 | 1.18% | Feb 23, 2026 |
| Alex C. Levit | Chief Legal Officer, Corp. Sec | 81,983 | 0.09% | Feb 23, 2026 |
| Jennifer Lynn Minai-Azary | Chief Financial Officer | 80,010 | 0.09% | Feb 23, 2026 |
| Karen Deborah Chagin | Chief Medical Officer | – | – | Feb 23, 2026 |
| Ullmann Claudio Dansky | Chief Medical Officer | – | – | Feb 14, 2025 |
| Andy Pasternak | Director | – | – | Jun 26, 2026 |
| Linda West | Director | – | – | Jun 26, 2026 |
| Karen L. Smith | Director | – | – | Jun 26, 2026 |
| Jennifer Evans Stacey | Director | – | – | Jun 26, 2026 |
| Philip W. Kantoff | Director | 3,533 | 0.00% | Jun 26, 2026 |
| Luke Nathaniel Walker | Director | – | – | Jun 26, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Martin A. Lehr Chief Executive Officer, Director | Jun 9, 2025 | Buy | +100,000 | $0.70 | $70.00K | 920,190 |
| Alex C. Levit Chief Legal Officer, Corp. Sec | Jun 6, 2025 | Buy | +20,000 | $0.58 | $11.60K | 29,000 |
| Jennifer Lynn Minai-Azary Chief Financial Officer | Jun 6, 2025 | Buy | +40,010 | $0.64 | $25.61K | 80,010 |
| Martin A. Lehr Chief Executive Officer, Director | Feb 21, 2023 | Buy | +5,823 | $0.84 | $4.89K | 159,701 |
| Martin A. Lehr Chief Executive Officer, Director | Feb 13, 2023 | Buy | +5,606 | $0.87 | $4.88K | 153,878 |
| Martin A. Lehr Chief Executive Officer, Director | Feb 6, 2023 | Buy | +5,040 | $0.97 | $4.89K | 148,272 |
| Martin A. Lehr Chief Executive Officer, Director | Jan 30, 2023 | Buy | +7,027 | $0.70 | $4.92K | 143,232 |
| Martin A. Lehr Chief Executive Officer, Director | Jan 23, 2023 | Buy | +6,839 | $0.72 | $4.92K | 136,205 |
| Martin A. Lehr Chief Executive Officer, Director | Jan 17, 2023 | Buy | +6,783 | $0.74 | $5.02K | 129,366 |
| Martin A. Lehr Chief Executive Officer, Director | Dec 16, 2022 | Buy | +20,000 | $0.74 | $14.80K | 122,583 |
| Jennifer Lynn Minai-Azary Chief Financial Officer | Dec 16, 2022 | Buy | +25,000 | $0.74 | $18.50K | 40,000 |
| Alex C. Levit Chief Legal Officer, Corp. Sec | Dec 9, 2022 | Buy | +6,000 | $0.85 | $5.10K | 9,000 |
| Martin A. Lehr Chief Executive Officer, Director | Aug 19, 2022 | Buy | +13,000 | $1.85 | $24.05K | 102,583 |
| Jennifer Lynn Minai-Azary Chief Financial Officer | Aug 17, 2022 | Buy | +15,000 | $1.80 | $27.00K | 15,000 |
| Tarek Sahmoud Chief Medical Officer | Aug 16, 2022 | Buy | +10,000 | $1.95 | $19.50K | 10,000 |
| Martin A. Lehr Chief Executive Officer, Director | Dec 16, 2021 | Buy | +13,000 | $3.22 | $41.86K | 820,190 |
| Martin A. Lehr Chief Executive Officer, Director | Oct 22, 2021 | Exercise | +52,680 | $7.14 | $376.14K | 0 |
| Martin A. Lehr Chief Executive Officer, Director | Oct 22, 2021 | Conversion | +210,715 | – | – | 210,715 |
| Martin A. Lehr Chief Executive Officer, Director | Oct 22, 2021 | Buy | +10,000 | $5.00 | $50.00K | 807,190 |
| Martin A. Lehr Chief Executive Officer, Director | Oct 22, 2021 | Conversion | +586,475 | – | – | 797,190 |
| Evan G. Dick SVP of R&D | Oct 22, 2021 | Conversion | +26,587 | – | – | 82,960 |
| Evan G. Dick SVP of R&D | Oct 22, 2021 | Conversion | +26,587 | – | – | 87,139 |
| Martin A. Lehr Chief Executive Officer, Director | Oct 22, 2021 | Conversion | +586,476 | – | – | 849,878 |
| Martin A. Lehr Chief Executive Officer, Director | Oct 22, 2021 | Exercise | +52,680 | $7.14 | $376.14K | 52,680 |
| Martin A. Lehr Chief Executive Officer, Director | Oct 22, 2021 | Buy | +10,000 | $5.00 | $50.00K | 99,583 |
| Martin A. Lehr Chief Executive Officer, Director | Oct 22, 2021 | Conversion | +210,722 | – | – | 263,402 |
| Alex C. Levit Chief Legal Officer, Corp. Sec | Oct 22, 2021 | Buy | +3,000 | $5.00 | $15.00K | 3,000 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.